ArticleJournal of bioethical inquiry2026
Manuscript Rejection on the Pretext of "Limited Space": An Ethical and Economic Dilemma.
Article in Journal of bioethical inquiry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In the digital age, where physical space constraints in scholarly publishing have largely diminished, the recurring editorial justification of "limited space" for manuscript rejection appears increasingly indefensible. This commentary critically examines the ethical and economic dimensions of this rationale, particularly when it results in redirection to fee-based open access (OA) sister journals. While peer-reviewed publication decisions are ideally grounded in scientific merit, novelty, and methodological rigor, the authors argue that the space limitation rationale may function as a pretext to curate journal branding or steer submissions toward revenue-generating platforms. The expansion of OA publishing, though intended to democratize knowledge dissemination, has in some cases evolved into a profit-driven model that imposes article processing charges on authors. Such practices risk compromising editorial transparency, fairness, and academic equity. The authors advocate for clearer editorial policies, increased transparency in decision-making, and the adoption of mechanisms such as dynamic submission dashboards to inform authors of real-time publication capacity. Rejections should be based on scholarly merit rather than logistical or commercial interests. This article calls for reinforcing the ethical foundations of academic publishing to ensure that decisions reflect genuine scholarly standards and not economic expediency.
Indexed as
Identifiers
41870869What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.